Cord Blood Banking Market to Near $50B
The global market for cord blood banking services is projected to reach $49.85 billion by 2031, up from its current valuation. The growth is being fueled by major advancements in stem cell therapies and regenerative medicine, along with increasing public awareness of the benefits of preserving cord blood. North America currently accounts for nearly 40% of the global market.
The hematopoietic stem cells found in cord blood are crucial for treating over 80 conditions, including various cancers, blood disorders like sickle cell anemia, and immune system deficiencies. More than 60,000 cord blood transplants have been performed globally to treat such diseases. Clinical trials are also exploring the use of these stem cells for conditions like autism, cerebral palsy, and diabetes. The first successful cord blood transplant occurred in 1988, treating a five-year-old with Fanconi's Anemia using stem cells from his newborn sister. This pioneering procedure established cord blood as a viable alternative to bone marrow transplants. A key advantage of cord blood is that it doesn't require a perfect genetic match between donor and recipient, reducing the risk of complications like graft-versus-host disease. Expectant parents can choose between private banking, for their family's exclusive use, or public donation. Private banking involves an initial fee of $1,500 to $3,000 and annual storage fees ranging from $150 to $300. Public donation is free, but the family gives up rights to the cord blood, which then becomes available to any matching patient in need. A significant challenge in cord blood therapy has been the limited number of stem cells in a single collection, which can be insufficient for treating adults. However, recent advancements in "cord blood expansion" technology are addressing this issue. In April 2023, the U.S. Food and Drug Administration (FDA) approved a procedure that can multiply the number of stem cells, expanding their therapeutic potential.
